Avanos Medical Q3 EPS Estimate Decreased by Zacks Research

Avanos Medical, Inc. (NYSE:AVNS) – Equities research analysts at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for Avanos Medical in a report released on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.30 per share for the quarter, down from their prior forecast of $0.43. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s FY2025 earnings at $1.20 EPS, Q2 2026 earnings at $0.30 EPS and FY2026 earnings at $1.48 EPS.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. The business had revenue of $179.60 million for the quarter, compared to analysts’ expectations of $177.23 million.

Separately, StockNews.com upgraded shares of Avanos Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 19th.

Avanos Medical Price Performance

Shares of AVNS opened at $14.41 on Monday. The firm has a market capitalization of $662.77 million, a PE ratio of 42.37 and a beta of 1.17. The company’s 50-day moving average is $15.80 and its 200-day moving average is $18.58. Avanos Medical has a fifty-two week low of $14.25 and a fifty-two week high of $25.36. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46.

Institutional Trading of Avanos Medical

A number of institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. increased its holdings in shares of Avanos Medical by 27.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock worth $47,941,000 after purchasing an additional 644,267 shares during the period. Tributary Capital Management LLC lifted its position in Avanos Medical by 38.1% during the fourth quarter. Tributary Capital Management LLC now owns 893,008 shares of the company’s stock worth $14,217,000 after purchasing an additional 246,379 shares during the period. Brown Advisory Inc. grew its stake in Avanos Medical by 12.0% during the fourth quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company’s stock worth $30,329,000 after buying an additional 204,218 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in Avanos Medical by 43.1% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company’s stock valued at $7,874,000 after buying an additional 148,902 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Avanos Medical by 189.8% in the 4th quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company’s stock valued at $3,210,000 after buying an additional 132,063 shares in the last quarter. Institutional investors own 95.17% of the company’s stock.

Insider Transactions at Avanos Medical

In related news, SVP Kerr Holbrook sold 7,000 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the transaction, the senior vice president now directly owns 82,047 shares in the company, valued at approximately $1,251,216.75. This represents a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.90% of the stock is owned by corporate insiders.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.